| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 44 | 2023 | 1032 | 6.810 |
Why?
|
| Neoplasms | 37 | 2023 | 1660 | 6.150 |
Why?
|
| Golgi Apparatus | 20 | 2009 | 75 | 4.510 |
Why?
|
| Smoking | 35 | 2022 | 1449 | 4.460 |
Why?
|
| Lung Neoplasms | 23 | 2022 | 1172 | 4.140 |
Why?
|
| Tobacco Use | 8 | 2021 | 98 | 3.050 |
Why?
|
| Tobacco | 9 | 2023 | 161 | 2.500 |
Why?
|
| Nicotine | 7 | 2022 | 350 | 1.850 |
Why?
|
| Medical Oncology | 7 | 2022 | 110 | 1.850 |
Why?
|
| Electronic Nicotine Delivery Systems | 7 | 2022 | 180 | 1.670 |
Why?
|
| Trypanosoma brucei brucei | 5 | 2009 | 20 | 1.450 |
Why?
|
| Cancer Survivors | 3 | 2020 | 145 | 1.400 |
Why?
|
| Membrane Proteins | 12 | 2008 | 617 | 1.300 |
Why?
|
| Head and Neck Neoplasms | 11 | 2022 | 561 | 1.260 |
Why?
|
| Humans | 107 | 2023 | 68525 | 1.220 |
Why?
|
| Tobacco Use Disorder | 7 | 2021 | 432 | 1.140 |
Why?
|
| Health Policy | 4 | 2015 | 221 | 1.070 |
Why?
|
| Cigarette Smoking | 4 | 2022 | 104 | 1.050 |
Why?
|
| Protozoan Proteins | 5 | 2008 | 25 | 1.010 |
Why?
|
| Electronic Health Records | 5 | 2021 | 374 | 0.950 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 1070 | 0.820 |
Why?
|
| Smoking Prevention | 5 | 2014 | 259 | 0.820 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 503 | 0.800 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 503 | 0.790 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 143 | 0.740 |
Why?
|
| COP-Coated Vesicles | 3 | 2005 | 3 | 0.740 |
Why?
|
| Coronavirus | 1 | 2020 | 16 | 0.740 |
Why?
|
| United States | 19 | 2023 | 7335 | 0.700 |
Why?
|
| Autoantigens | 5 | 2008 | 91 | 0.690 |
Why?
|
| Early Detection of Cancer | 4 | 2019 | 439 | 0.680 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2016 | 624 | 0.650 |
Why?
|
| Mitosis | 5 | 2004 | 76 | 0.640 |
Why?
|
| Vaping | 1 | 2019 | 124 | 0.620 |
Why?
|
| Research | 2 | 2016 | 214 | 0.620 |
Why?
|
| Tobacco Industry | 2 | 2015 | 55 | 0.620 |
Why?
|
| Vesicular Transport Proteins | 4 | 2008 | 87 | 0.580 |
Why?
|
| Pandemics | 6 | 2023 | 346 | 0.570 |
Why?
|
| Cytoskeletal Proteins | 3 | 2005 | 108 | 0.550 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 122 | 0.530 |
Why?
|
| Self Report | 3 | 2021 | 370 | 0.520 |
Why?
|
| American Medical Association | 1 | 2015 | 21 | 0.520 |
Why?
|
| Cell Cycle | 5 | 2009 | 312 | 0.500 |
Why?
|
| Enzyme Induction | 1 | 2014 | 118 | 0.490 |
Why?
|
| Toxoplasma | 2 | 2005 | 23 | 0.490 |
Why?
|
| Cell Proliferation | 3 | 2019 | 1173 | 0.480 |
Why?
|
| Smoke | 1 | 2014 | 46 | 0.480 |
Why?
|
| Female | 44 | 2022 | 38015 | 0.480 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 369 | 0.470 |
Why?
|
| Tobacco Use Cessation | 3 | 2020 | 44 | 0.460 |
Why?
|
| Male | 42 | 2022 | 37281 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 772 | 0.460 |
Why?
|
| Middle Aged | 34 | 2022 | 21119 | 0.450 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 183 | 0.450 |
Why?
|
| Adult | 30 | 2023 | 21375 | 0.440 |
Why?
|
| Aged | 28 | 2022 | 14842 | 0.420 |
Why?
|
| Endoplasmic Reticulum | 4 | 2008 | 148 | 0.420 |
Why?
|
| Cell Movement | 1 | 2014 | 630 | 0.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2019 | 300 | 0.400 |
Why?
|
| Membrane Fusion | 2 | 2008 | 7 | 0.390 |
Why?
|
| Exocytosis | 2 | 2008 | 34 | 0.380 |
Why?
|
| Radiosurgery | 4 | 2017 | 66 | 0.380 |
Why?
|
| Animals | 23 | 2020 | 20877 | 0.370 |
Why?
|
| Cell Fractionation | 3 | 2005 | 34 | 0.360 |
Why?
|
| Radiation Tolerance | 2 | 2007 | 30 | 0.360 |
Why?
|
| Tobacco Products | 1 | 2013 | 234 | 0.360 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 442 | 0.360 |
Why?
|
| Counseling | 4 | 2021 | 279 | 0.350 |
Why?
|
| Apoptosis | 2 | 2014 | 1640 | 0.340 |
Why?
|
| Calcium-Binding Proteins | 2 | 2008 | 114 | 0.340 |
Why?
|
| Cell Cycle Proteins | 2 | 2008 | 230 | 0.330 |
Why?
|
| Organelles | 1 | 2008 | 18 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2008 | 411 | 0.330 |
Why?
|
| NF-kappa B | 3 | 2007 | 432 | 0.320 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 848 | 0.320 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 445 | 0.320 |
Why?
|
| Biomarkers | 4 | 2019 | 1593 | 0.310 |
Why?
|
| Esophageal Neoplasms | 3 | 2013 | 150 | 0.310 |
Why?
|
| Algorithms | 2 | 2019 | 1194 | 0.310 |
Why?
|
| Protein Transport | 5 | 2008 | 280 | 0.300 |
Why?
|
| Chemoradiotherapy | 4 | 2016 | 54 | 0.300 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 154 | 0.300 |
Why?
|
| Precision Medicine | 2 | 2020 | 111 | 0.290 |
Why?
|
| Prognosis | 8 | 2020 | 2093 | 0.290 |
Why?
|
| Leupeptins | 1 | 2006 | 23 | 0.280 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 29 | 0.280 |
Why?
|
| Microscopy, Video | 6 | 2005 | 27 | 0.280 |
Why?
|
| Centrosome | 1 | 2005 | 6 | 0.280 |
Why?
|
| Neoplasm Staging | 10 | 2020 | 799 | 0.280 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 73 | 0.270 |
Why?
|
| Microscopy, Fluorescence | 6 | 2008 | 261 | 0.270 |
Why?
|
| Health Care Costs | 2 | 2019 | 346 | 0.270 |
Why?
|
| Microscopy, Immunoelectron | 4 | 2009 | 27 | 0.270 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2005 | 19 | 0.260 |
Why?
|
| Government Regulation | 2 | 2015 | 46 | 0.260 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 237 | 0.250 |
Why?
|
| Cotinine | 3 | 2015 | 40 | 0.250 |
Why?
|
| Surveys and Questionnaires | 6 | 2016 | 2798 | 0.250 |
Why?
|
| Risk Factors | 5 | 2016 | 5719 | 0.250 |
Why?
|
| Software | 1 | 2007 | 418 | 0.240 |
Why?
|
| Aged, 80 and over | 12 | 2018 | 4843 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 467 | 0.240 |
Why?
|
| Rats | 8 | 2005 | 5300 | 0.240 |
Why?
|
| rab1 GTP-Binding Proteins | 1 | 2003 | 1 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2007 | 778 | 0.230 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 791 | 0.230 |
Why?
|
| Adenocarcinoma | 3 | 2017 | 475 | 0.220 |
Why?
|
| Risk Assessment | 6 | 2016 | 2004 | 0.220 |
Why?
|
| Carrier Proteins | 2 | 2006 | 597 | 0.220 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 163 | 0.220 |
Why?
|
| Nitrosamines | 1 | 2022 | 18 | 0.220 |
Why?
|
| Public Health | 2 | 2015 | 201 | 0.220 |
Why?
|
| Inpatients | 2 | 2021 | 208 | 0.220 |
Why?
|
| Treatment Failure | 3 | 2019 | 216 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 536 | 0.210 |
Why?
|
| Luminescent Proteins | 4 | 2006 | 57 | 0.210 |
Why?
|
| Survival Analysis | 5 | 2017 | 714 | 0.210 |
Why?
|
| Betacoronavirus | 2 | 2020 | 116 | 0.210 |
Why?
|
| Data Collection | 2 | 2013 | 420 | 0.200 |
Why?
|
| Smokers | 2 | 2020 | 198 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 2323 | 0.200 |
Why?
|
| Societies, Medical | 2 | 2015 | 403 | 0.200 |
Why?
|
| Canada | 1 | 2022 | 266 | 0.200 |
Why?
|
| Aftercare | 2 | 2021 | 114 | 0.200 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 117 | 0.200 |
Why?
|
| Lymph Nodes | 2 | 2013 | 258 | 0.200 |
Why?
|
| Green Fluorescent Proteins | 4 | 2005 | 200 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 444 | 0.200 |
Why?
|
| HeLa Cells | 3 | 2008 | 237 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2019 | 154 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2020 | 7028 | 0.190 |
Why?
|
| Comorbidity | 3 | 2020 | 1425 | 0.190 |
Why?
|
| Motivation | 2 | 2021 | 561 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2008 | 376 | 0.190 |
Why?
|
| Pregnancy | 3 | 2021 | 2331 | 0.190 |
Why?
|
| Intensive Care Units | 1 | 2022 | 344 | 0.190 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 951 | 0.180 |
Why?
|
| Michigan | 1 | 2020 | 68 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2020 | 40 | 0.180 |
Why?
|
| Hotlines | 1 | 2020 | 51 | 0.180 |
Why?
|
| Antineoplastic Protocols | 1 | 2019 | 4 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 75 | 0.180 |
Why?
|
| Communication Barriers | 1 | 2019 | 48 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 101 | 0.170 |
Why?
|
| Hospitalization | 3 | 2023 | 977 | 0.170 |
Why?
|
| Cohort Studies | 8 | 2022 | 2356 | 0.170 |
Why?
|
| Mandible | 1 | 2019 | 53 | 0.170 |
Why?
|
| Receptors, Nicotinic | 1 | 2019 | 41 | 0.170 |
Why?
|
| Skull | 1 | 2019 | 63 | 0.170 |
Why?
|
| Organogenesis | 1 | 2019 | 49 | 0.170 |
Why?
|
| Advisory Committees | 2 | 2016 | 73 | 0.170 |
Why?
|
| Income | 1 | 2019 | 165 | 0.170 |
Why?
|
| Educational Status | 1 | 2019 | 273 | 0.170 |
Why?
|
| Lung | 2 | 2021 | 849 | 0.160 |
Why?
|
| Carcinogens | 2 | 2022 | 86 | 0.160 |
Why?
|
| Protein Binding | 3 | 2008 | 1027 | 0.160 |
Why?
|
| Cell Line | 4 | 2007 | 1752 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 955 | 0.160 |
Why?
|
| Hospital Administration | 1 | 2018 | 43 | 0.160 |
Why?
|
| Phosphorylation | 4 | 2022 | 1199 | 0.160 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 12 | 0.160 |
Why?
|
| Coat Protein Complex I | 2 | 2008 | 3 | 0.160 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 3 | 0.160 |
Why?
|
| Health Behavior | 1 | 2021 | 458 | 0.150 |
Why?
|
| Anxiety | 1 | 2020 | 422 | 0.150 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 146 | 0.150 |
Why?
|
| Tonsillar Neoplasms | 1 | 2016 | 7 | 0.150 |
Why?
|
| Nephrectomy | 1 | 2017 | 103 | 0.150 |
Why?
|
| Tongue Neoplasms | 1 | 2016 | 28 | 0.150 |
Why?
|
| Immunoprecipitation | 2 | 2008 | 132 | 0.140 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 700 | 0.140 |
Why?
|
| SEER Program | 5 | 2016 | 150 | 0.140 |
Why?
|
| Prevalence | 2 | 2019 | 1609 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 110 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2005 | 753 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 304 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 284 | 0.140 |
Why?
|
| Cannabis | 1 | 2018 | 115 | 0.140 |
Why?
|
| Judgment | 1 | 2016 | 40 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 131 | 0.140 |
Why?
|
| Voluntary Health Agencies | 1 | 2015 | 4 | 0.140 |
Why?
|
| Sex Factors | 1 | 2019 | 1265 | 0.140 |
Why?
|
| Sesquiterpenes | 2 | 2007 | 41 | 0.140 |
Why?
|
| Mental Recall | 1 | 2016 | 72 | 0.140 |
Why?
|
| Comprehension | 1 | 2016 | 71 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 22 | 0.140 |
Why?
|
| Models, Biological | 1 | 2020 | 981 | 0.130 |
Why?
|
| Jurisprudence | 1 | 2015 | 11 | 0.130 |
Why?
|
| Social Support | 1 | 2018 | 423 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2018 | 267 | 0.130 |
Why?
|
| Self Disclosure | 1 | 2015 | 55 | 0.130 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 92 | 0.130 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2012 | 30 | 0.130 |
Why?
|
| Binding Sites | 2 | 2008 | 631 | 0.130 |
Why?
|
| Age Factors | 1 | 2019 | 1860 | 0.130 |
Why?
|
| Microscopy, Confocal | 2 | 2007 | 337 | 0.130 |
Why?
|
| Florida | 1 | 2015 | 221 | 0.130 |
Why?
|
| Microscopy, Electron | 2 | 2005 | 351 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 349 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2016 | 212 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 438 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2012 | 3702 | 0.120 |
Why?
|
| Dimerization | 2 | 2004 | 99 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2015 | 310 | 0.120 |
Why?
|
| Policy Making | 1 | 2014 | 51 | 0.120 |
Why?
|
| Salivary Ducts | 1 | 2013 | 1 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 322 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 267 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 332 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2012 | 294 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 61 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 248 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2013 | 621 | 0.120 |
Why?
|
| Nutritional Status | 2 | 2013 | 112 | 0.120 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2013 | 2 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2018 | 7264 | 0.120 |
Why?
|
| Endosomes | 2 | 2004 | 45 | 0.120 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 53 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 222 | 0.120 |
Why?
|
| Mass Screening | 1 | 2019 | 837 | 0.120 |
Why?
|
| Adolescent | 3 | 2022 | 8903 | 0.110 |
Why?
|
| Depression | 1 | 2020 | 942 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2013 | 23 | 0.110 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2013 | 40 | 0.110 |
Why?
|
| Young Adult | 3 | 2020 | 5708 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 371 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 127 | 0.110 |
Why?
|
| Marketing | 1 | 2013 | 26 | 0.110 |
Why?
|
| Endocytosis | 2 | 2004 | 113 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2018 | 880 | 0.110 |
Why?
|
| Public Opinion | 1 | 2013 | 32 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2013 | 64 | 0.110 |
Why?
|
| Mice | 5 | 2020 | 8472 | 0.110 |
Why?
|
| Decision Making | 1 | 2016 | 410 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2012 | 1085 | 0.110 |
Why?
|
| Macular Edema | 1 | 2012 | 21 | 0.110 |
Why?
|
| Carbonic Anhydrases | 1 | 2012 | 18 | 0.110 |
Why?
|
| Cell Survival | 2 | 2012 | 901 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 40 | 0.110 |
Why?
|
| Autophagy | 1 | 2014 | 207 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 36 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 76 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 71 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 189 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2023 | 35 | 0.100 |
Why?
|
| Cell Membrane | 2 | 2004 | 523 | 0.100 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 1 | 2011 | 6 | 0.100 |
Why?
|
| Mediastinum | 1 | 2011 | 39 | 0.100 |
Why?
|
| Forecasting | 1 | 2013 | 277 | 0.100 |
Why?
|
| Risk | 1 | 2013 | 563 | 0.100 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2011 | 10 | 0.100 |
Why?
|
| Esophagogastric Junction | 1 | 2011 | 118 | 0.100 |
Why?
|
| Hypoxia | 1 | 2012 | 169 | 0.100 |
Why?
|
| Nose Neoplasms | 1 | 2011 | 25 | 0.100 |
Why?
|
| Random Allocation | 1 | 2012 | 442 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2011 | 86 | 0.100 |
Why?
|
| Quality of Life | 4 | 2021 | 1515 | 0.100 |
Why?
|
| Radiotherapy | 2 | 2011 | 86 | 0.100 |
Why?
|
| Nasal Cavity | 1 | 2011 | 62 | 0.100 |
Why?
|
| Weight Loss | 1 | 2013 | 319 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2011 | 72 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 2264 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 1849 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 361 | 0.090 |
Why?
|
| Time Factors | 4 | 2018 | 4655 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 142 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2008 | 954 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 127 | 0.080 |
Why?
|
| Survival Rate | 3 | 2019 | 1055 | 0.080 |
Why?
|
| Endopeptidases | 1 | 2008 | 51 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 424 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 27 | 0.080 |
Why?
|
| Viral Envelope Proteins | 2 | 2005 | 43 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2019 | 100 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2004 | 2673 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2007 | 852 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 657 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 104 | 0.080 |
Why?
|
| Liver | 2 | 2003 | 1118 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2008 | 246 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2021 | 383 | 0.080 |
Why?
|
| South Carolina | 3 | 2018 | 2750 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1465 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2014 | 2688 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 107 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 3256 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 72 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 1 | 2006 | 78 | 0.070 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 40 | 0.070 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 35 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 160 | 0.070 |
Why?
|
| Biological Transport | 1 | 2006 | 210 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2008 | 483 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 331 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2006 | 141 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 370 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 765 | 0.070 |
Why?
|
| Biotinylation | 1 | 2005 | 27 | 0.070 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2005 | 6 | 0.060 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2004 | 17 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 165 | 0.060 |
Why?
|
| Glass | 1 | 2005 | 28 | 0.060 |
Why?
|
| Proline | 1 | 2004 | 52 | 0.060 |
Why?
|
| Cytosol | 1 | 2004 | 123 | 0.060 |
Why?
|
| Serine | 1 | 2004 | 99 | 0.060 |
Why?
|
| Flagella | 1 | 2004 | 2 | 0.060 |
Why?
|
| Fibroadenoma | 1 | 2004 | 2 | 0.060 |
Why?
|
| Endoplasmic Reticulum, Rough | 1 | 2004 | 3 | 0.060 |
Why?
|
| Interphase | 1 | 2004 | 19 | 0.060 |
Why?
|
| Quinones | 1 | 2004 | 13 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2004 | 122 | 0.060 |
Why?
|
| Palliative Care | 2 | 2020 | 271 | 0.060 |
Why?
|
| Boron Compounds | 1 | 2004 | 21 | 0.060 |
Why?
|
| Ultrasonography, Mammary | 1 | 2004 | 39 | 0.060 |
Why?
|
| Diffusion | 1 | 2004 | 90 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 282 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2004 | 66 | 0.060 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 166 | 0.060 |
Why?
|
| Cell-Free System | 1 | 2003 | 43 | 0.060 |
Why?
|
| Cryoelectron Microscopy | 1 | 2003 | 9 | 0.060 |
Why?
|
| Microinjections | 1 | 2003 | 130 | 0.060 |
Why?
|
| Immunoassay | 1 | 2003 | 64 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 91 | 0.060 |
Why?
|
| Wisconsin | 1 | 2023 | 30 | 0.060 |
Why?
|
| Plasmids | 1 | 2004 | 258 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 929 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 742 | 0.060 |
Why?
|
| Transgenes | 1 | 2002 | 92 | 0.050 |
Why?
|
| Qc-SNARE Proteins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 215 | 0.050 |
Why?
|
| Qb-SNARE Proteins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 58 | 0.050 |
Why?
|
| R-SNARE Proteins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Qa-SNARE Proteins | 1 | 2002 | 5 | 0.050 |
Why?
|
| Detergents | 1 | 2002 | 34 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 2002 | 41 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2002 | 18 | 0.050 |
Why?
|
| Intubation, Intratracheal | 1 | 2022 | 99 | 0.050 |
Why?
|
| Transfection | 1 | 2004 | 782 | 0.050 |
Why?
|
| Universities | 1 | 2023 | 191 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 541 | 0.050 |
Why?
|
| Disease Progression | 2 | 2017 | 1037 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1039 | 0.050 |
Why?
|
| Documentation | 1 | 2021 | 83 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2002 | 305 | 0.050 |
Why?
|
| Oncologists | 1 | 2020 | 9 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2022 | 384 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1446 | 0.050 |
Why?
|
| Nomograms | 1 | 2020 | 19 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 41 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 1174 | 0.050 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.050 |
Why?
|
| Europe | 1 | 2020 | 195 | 0.050 |
Why?
|
| Medicare | 1 | 2022 | 316 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2020 | 49 | 0.050 |
Why?
|
| International Cooperation | 1 | 2020 | 88 | 0.050 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.050 |
Why?
|
| Ceramides | 1 | 2004 | 578 | 0.050 |
Why?
|
| Heterografts | 1 | 2020 | 70 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1046 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 93 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 78 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 130 | 0.040 |
Why?
|
| Molar | 1 | 2019 | 27 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 57 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 50 | 0.040 |
Why?
|
| Emotions | 1 | 2020 | 244 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 1582 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2019 | 75 | 0.040 |
Why?
|
| Thorax | 1 | 2018 | 49 | 0.040 |
Why?
|
| New York | 1 | 2018 | 223 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 261 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 160 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 730 | 0.040 |
Why?
|
| Logistic Models | 2 | 2012 | 1419 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2002 | 902 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 467 | 0.040 |
Why?
|
| Language Tests | 1 | 2016 | 36 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 306 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.030 |
Why?
|
| Alberta | 1 | 2015 | 15 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 87 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 129 | 0.030 |
Why?
|
| Telemetry | 1 | 2015 | 23 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 279 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 63 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 652 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 162 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 1533 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2013 | 26 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2013 | 24 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 125 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 110 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1341 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2012 | 10 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 128 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2012 | 95 | 0.030 |
Why?
|
| Hypoadrenocorticism, Familial | 1 | 2011 | 3 | 0.030 |
Why?
|
| Glycerol Kinase | 1 | 2011 | 3 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 125 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2011 | 72 | 0.030 |
Why?
|
| Geography | 1 | 2011 | 80 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2011 | 69 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 152 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 242 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 170 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 737 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 60 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 866 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2007 | 64 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 149 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1851 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 331 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 614 | 0.020 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2004 | 1 | 0.020 |
Why?
|
| Palpation | 1 | 2004 | 21 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2004 | 89 | 0.020 |
Why?
|
| Transferrin | 1 | 2004 | 94 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 76 | 0.020 |
Why?
|
| Dogs | 1 | 2004 | 490 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 756 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 331 | 0.010 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2002 | 15 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2004 | 205 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 161 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 262 | 0.010 |
Why?
|